SequelSEC

AIM ImmunoTech Inc. AIM

Biological Products, (No Diagnostic Substances) · CIK 0000946644 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$26.00K
Fiscal year ended 2026-06-30
Operating income
-$3.51M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$6.41MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.79Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue72.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin-15861.4%9th
Operating margin-13254.5%12th
Current ratio0.53x13th
R&D / revenue4459.1%83th
Revenue YoY growth-48.2%22th
SBC / revenue68.2%64th

AIM ImmunoTech Inc. (AIM) reported revenue of $26.00K and net income of -$3.79M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from AIM ImmunoTech Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

AIM ImmunoTech Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$26.00K$22.00K$21.00K$26.00K$25.00K$16.00K$45.00K$35.00K$50.00K$40.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$3.51M-$2.23M-$2.95M-$2.45M-$2.65M-$3.62M-$5.86M-$4.49M-$3.69M-$5.73M
Net income-$3.79M-$3.02M-$4.18M-$3.28M-$2.79M-$3.70M-$5.97M-$3.70M-$1.84M-$5.82M
Research & development$589.00K$482.00K$1.06M$607.00K$1.17M$1.08M$1.66M$1.44M$1.14M$1.95M
Weighted-average diluted sharesshares 17.12Mshares 4.35MUnavailableshares 2.09MUnavailableUnavailableUnavailableUnavailableUnavailableshares 49.46M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.43$-0.69Unavailable$1.57$-3.68$-0.05Unavailable$-6.00$-3.00$-0.12
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.94M$1.76M$1.87M$1.80M$1.49M$2.54M$4.23M$3.08M$2.59M$3.82M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

AIM ImmunoTech Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$9.90M$5.82M$2.98M$2.35M$476.00K$898.00K$1.70M$915.00K$3.55M$3.30M
Total assets$12.73M$8.58M$5.78M$5.49M$4.13M$6.25M$8.61M$13.59M$15.72M$16.19M
Current assets$10.43M$6.21M$3.30M$2.58M$1.02M$2.58M$4.18M$7.57M$10.36M$11.31M
Total liabilities$4.99M$6.46M$15.56M$11.57M$10.68M$10.10M$9.93M$10.68M$9.61M$11.36M
Current liabilities$4.95M$6.14M$6.22M$4.04M$10.39M$9.77M$9.54M$10.10M$8.84M$9.88M
Total equity incl. NCI$7.74M$2.12M-$9.78M-$6.08M-$6.55M-$3.86M-$1.32M$2.91M$6.10M$4.83M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailable$7.00KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$3.62M$210.00K$927.00KUnavailable$2.72M$2.39M$2.81M$139.00K$283.00K$950.00K
Accounts payable$480.00K$1.22M$1.63M$1.25M$7.30M$6.94M$6.38M$6.26M$5.46M$6.57M

Cash flow

AIM ImmunoTech Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$4.59M-$2.72M-$1.99M-$5.08M-$1.53M-$2.36M-$3.96M-$3.11M-$3.01M-$4.82M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailable
Investing cash flow-$112.00K-$37.00K-$95.00K$296.00K$754.00K$898.00K$3.70M$334.00K$826.00K-$158.00K
Financing cash flow$8.79M$5.59M$2.72M$6.65M$355.00K$660.00K$1.04M$137.00K$2.44M$2.83M
Net change in cash$4.08M$2.83M$638.00K$1.87M-$422.00K-$803.00K$786.00K-$2.64M$259.00K-$2.14M
Stock-based compensationUnavailableUnavailable$0$0$0$60.00K$196.00K$80.00K$80.00K$80.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

AIM ImmunoTech Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$3.96MUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-13511.5%-10118.2%-14057.1%-9411.5%-10584.0%-22618.8%-13011.1%-12825.7%-7388.0%-14335.0%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-8788.9%UnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailable0.0%0.0%0.0%375.0%435.6%UnavailableUnavailable200.0%
Current ratio2.11x1.01x0.53x0.64x0.10x0.26x0.44x0.75x1.17x1.14x
Revenue YoY growth4.0%37.5%-53.3%-25.7%-50.0%-60.0%-30.8%-23.9%19.0%-18.4%
Net margin-14569.2%Unavailable-19881.0%-12630.8%-11176.0%Unavailable-13260.0%-10571.4%UnavailableUnavailable
R&D / revenue2265.4%2190.9%5061.9%2334.6%4696.0%6750.0%3697.8%4105.7%2290.0%4877.5%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailable
Long-term debt / equity0.47xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AIM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-27View SEC filing
10-Q · Filed 2025-11-17View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.